- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Canntab Therapeutics recently got featured on ABN Newswire on an article about Queensland Bauxite Ltd half yearly report.
Canntab Therapeutics recently got featured on ABN Newswire on an article about
VitaCann which is a subsidiary of Medical Cannabis, which is owned by Queensland Bauxite (ASX:QBL), “entered into an exclusive 50/50 Joint venture partnership with the Canadian Canntab company which has developed a unique world first Cannabis GMP Pharmaceutical Grade Extended Release (XR) pill that comes in a number of formulas intended to treat different illnesses such as chronic pain, anxiety and epilepsy” The article states.
Click here to read the full article.
Click here to connect with Canntab Therapeutics for an Investor Presentation.
Source: www.abnnewswire.net
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.